What is CJC-1295?
6 min read · Updated July 2026 · MY PEPTIDES Research Team
Key facts
CJC-1295 (without DAC) is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) carrying targeted amino-acid substitutions that improve its stability compared with the native peptide. Because it lacks the drug-affinity complex (DAC) of conjugated versions, it shows pharmacokinetic behaviour typical of non-conjugated GHRH analogues in experimental settings. In biochemical and cellular models it binds to and activates the GHRH receptor on pituitary-derived cells, triggering intracellular signalling involved in endocrine regulation, and published work has explored its receptor-binding, activation kinetics and downstream signalling under short-duration exposure. Observed effects vary with concentration, exposure time and experimental design, so it is used to characterise GHRH-receptor signalling rather than to infer physiological outcomes, and is frequently studied alongside the secretagogue ipamorelin. MY PEPTIDES supplies CJC-1295 as a pre-mixed solution with a batch-specific Certificate of Analysis (HPLC and mass spectrometry), stored refrigerated at 2–8°C. It is supplied strictly for in-vitro laboratory research use only — not for human or veterinary use, and carries no therapeutic claims.
CJC-1295 (without DAC) is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) carrying targeted amino-acid substitutions that improve its stability compared with the native peptide. Because it lacks the drug-affinity complex (DAC) of conjugated versions, it shows the pharmacokinetic behaviour typical of non-conjugated GHRH analogues in experimental settings.
Research use only. CJC-1295 is supplied strictly for in-vitro laboratory research. This page does not describe dosing, administration, or use in humans or animals, and makes no therapeutic claims.
What researchers study
In biochemical and cellular model systems, CJC-1295 binds to and activates the GHRH receptor on pituitary-derived cells, triggering intracellular signalling involved in endocrine regulation. Research has explored its receptor-binding behaviour, activation kinetics and downstream signalling under short-duration exposure conditions. As with all such peptides, observed effects vary with concentration, exposure time and experimental design, so it is used to characterise GHRH-receptor signalling rather than to infer defined physiological outcomes.
Typical research applications include:
- Analysing GHRH-receptor binding, activation and signalling dynamics
- Studying growth-hormone-axis regulation and endocrine feedback pathways
- Cellular assays evaluating transcriptional and downstream signalling responses
Studied alongside ipamorelin
A frequent theme in the literature is the pairing of a GHRH analogue with a growth-hormone secretagogue. For that reason researchers often study CJC-1295 and Ipamorelin together to compare convergent versus independent receptor signalling in the same model.
How it is supplied
CJC-1295 is supplied as a pre-mixed solution with a batch-specific Certificate of Analysis (HPLC + mass spectrometry), stored refrigerated at 2–8°C.
Related reading
- New to the topic? Start with what are research peptides?
CJC-1295
Available now from MY PEPTIDES — 99%+ purity, COA with every order, fast UK dispatch.
Frequently asked questions
- What is CJC-1295?
- A synthetic GHRH (1-29) analogue used in laboratory research to study growth-hormone-axis receptor signalling. Supplied for in-vitro research use only.
- Is CJC-1295 studied with ipamorelin?
- In the literature a GHRH analogue is often examined alongside a growth-hormone secretagogue such as ipamorelin to compare receptor signalling. Both are supplied for research use only.